Reduced connectivity in anterior cingulate cortex as an early predictor for treatment response in drug-naive, first-episode schizophrenia: A global-brain functional connectivity analysis
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
UMass Chan Affiliations
Department of PsychiatryDocument Type
Journal ArticlePublication Date
2019-09-12Keywords
Global-brain functional connectivityOlanzapine
Pattern classification
Schizophrenia
Treatment predictor
Mental Disorders
Nervous System
Neuroscience and Neurobiology
Psychiatry
Therapeutics
Metadata
Show full item recordAbstract
BACKGROUND: Antipsychotic medications may have acute effect on brain functional connectivity (FC) after only a few days of treatment. It is unclear if early changes in FC can predict treatment response in patients with schizophrenia. METHODS: The study included 32 patients with drug-naive, first-episode schizophrenia and 32 healthy controls. Resting-state functional magnetic resonance imaging was obtained from the patients at two time-points (pre-treatment baseline and 1week after treatment) and healthy controls at baseline. Patients were treated with olanzapine for 8weeks, and clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) at three time points (baseline, 1week and 8weeks after treatment). Imaging data were analyzed using global-brain FC (GFC) and support vector regression (SVR). RESULTS: At baseline, an increased GFC was observed in bilateral anterior cingulate cortex (ACC) in patients compared with healthy controls. After 1week of olanzapine treatment, patients showed decreased GFC in bilateral ACC compared to the baseline values. SVR analysis suggested a positive relationship between GFC changes in bilateral ACC at week 1 and improvement in negative symptoms at week 8 (r=0.957, p < 0.001). CONCLUSION: An early decrease in GFC in bilateral ACC may serve as a predictor for treatment response in patients with schizophrenia. If further confirmed, our finding may be able to help clinicians decide, during the early treatment course, whether the patient should stay on the chosen antipsychotic medication or switch to a different one.Source
Schizophr Res. 2019 Sep 12. pii: S0920-9964(19)30395-0. doi: 10.1016/j.schres.2019.09.003. [Epub ahead of print] Link to article on publisher's site
DOI
10.1016/j.schres.2019.09.003Permanent Link to this Item
http://hdl.handle.net/20.500.14038/46350PubMed ID
31522869Related Resources
ae974a485f413a2113503eed53cd6c53
10.1016/j.schres.2019.09.003